How to make latest cancer therapies also available for children with rare cancers
How adult drugs from the group of MAP kinase inhibitors can also be used in children with cancer in a standardized manner worldwide has now been outlined in a statement in the renowned European Journal of Cancer.
The authors of this review are stakeholders from all relevant fields. A major goal of the initiative is to test the most effective and tolerable MAP kinase inhibitor in clinical trials, thus enabling rapid market approval and availability for children.
Note: Comments are for discussion and clarification only. For medical advice, please consult with a healthcare professional.
Be the first to share your thoughts!
Evolution 2.0: What makes cancer more malignant
This data presents a snapshot of cancer in Europe, including its high prevalence, common types, age and gender distribut...
Discover Complementary and Alternative Medicine (CAM), a holistic approach to health focusing on mind, body, and spirit....
